Lifitegrast Patent Expiration
Lifitegrast is Used for relieving symptoms of dry eye disease. It was first introduced by Bausch And Lomb Inc
Lifitegrast Patents
Given below is the list of patents protecting Lifitegrast, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xiidra | US11058677 | LFA-1 inhibitor formulations | Dec 18, 2033 | Bausch And Lomb Inc |
| Xiidra | US9085553 | LFA-1 inhibitor and methods of preparation and polymorph thereof | Jul 25, 2033 | Bausch And Lomb Inc |
| Xiidra | US8927574 | Crystalline pharmaceutical and methods of preparation and use thereof | Nov 12, 2030 | Bausch And Lomb Inc |
| Xiidra | US9353088 | Crystalline pharmaceutical and methods of preparation and use thereof | Oct 21, 2030 | Bausch And Lomb Inc |
| Xiidra | US9890141 | Crystalline pharmaceutical and methods of preparation and use thereof | Oct 21, 2030 | Bausch And Lomb Inc |
| Xiidra | US8168655 | Compositions and methods for treatment of eye disorders | May 09, 2029 | Bausch And Lomb Inc |
| Xiidra | US8367701 | Crystalline pharmaceutical and methods of preparation and use thereof | Apr 15, 2029 | Bausch And Lomb Inc |
| Xiidra | US9447077 | Crystalline pharmaceutical and methods of preparation and use thereof | Apr 15, 2029 | Bausch And Lomb Inc |
| Xiidra | US8084047 | Compositions and methods for treatment of eye disorders | May 17, 2026 | Bausch And Lomb Inc |
| Xiidra | US8592450 | Compositions and methods for treatment of eye disorders | May 17, 2026 | Bausch And Lomb Inc |
| Xiidra | US7314938 | Modulators of cellular adhesion |
Mar 10, 2025
(Expired) | Bausch And Lomb Inc |
| Xiidra | US10124000 | Modulators of cellular adhesion |
Nov 05, 2024
(Expired) | Bausch And Lomb Inc |
| Xiidra | US7745460 | Modulators of cellular adhesion |
Nov 05, 2024
(Expired) | Bausch And Lomb Inc |
| Xiidra | US7790743 | Modulators of cellular adhesion |
Nov 05, 2024
(Expired) | Bausch And Lomb Inc |
| Xiidra | US7928122 | Modulators of cellular adhesion |
Nov 05, 2024
(Expired) | Bausch And Lomb Inc |
| Xiidra | US9216174 | Modulators of cellular adhesion |
Nov 05, 2024
(Expired) | Bausch And Lomb Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lifitegrast's patents.
Latest Legal Activities on Lifitegrast's Patents
Given below is the list recent legal activities going on the following patents of Lifitegrast.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Withdrawal of Application for PTE Critical | 02 Jul, 2024 | US8084047 |
| Withdrawal of Application for PTE Critical | 02 Jul, 2024 | US8168655 |
| Withdrawal of Application for PTE Critical | 02 Jul, 2024 | US8592450 |
| Notice of Final Determination -Eligible | 02 Jul, 2024 | US7314938 |
| Withdrawal of Application for PTE Critical | 02 Jul, 2024 | US7790743 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Feb, 2024 | US9447077 |
| Paralegal TD Not accepted | 14 Feb, 2024 | US7314938 |
| Email Notification Critical | 17 Jan, 2024 | US7314938 |
| Change in Power of Attorney (May Include Associate POA) Critical | 17 Jan, 2024 | US7314938 |
| Email Notification Critical | 05 Jan, 2024 | US8592450 |
Lifitegrast's Family Patents
Explore Our Curated Drug Screens
Lifitegrast Generic API Manufacturers
Several generic applications have been filed for Lifitegrast. The first generic version for Lifitegrast was by Micro Labs Ltd and was approved on Aug 4, 2023. And the latest generic version is by Ingenus Pharmaceuticals Llc and was approved on Oct 3, 2024.
Given below is the list of companies who have filed for Lifitegrast generic, along with the locations of their manufacturing plants worldwide.
1. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Lifitegrast. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5% | solution/drops | Discontinued | OPHTHALMIC | N/A | Nov 7, 2023 |
Manufacturing Plant Locations New
Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| India |
| |||||||
2. INGENUS PHARMS LLC
Ingenus Pharmaceuticals Llc has filed for 1 generic for Lifitegrast. Given below are the details of the strengths of this generic introduced by Ingenus Pharms Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5% | solution/drops | Discontinued | OPHTHALMIC | N/A | Oct 3, 2024 |
3. MICRO LABS
Micro Labs Ltd has filed for 1 generic for Lifitegrast. Given below are the details of the strengths of this generic introduced by Micro Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5% | solution/drops | Discontinued | OPHTHALMIC | N/A | Aug 4, 2023 |
Manufacturing Plant Locations New
Micro Labs's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Micro Labs as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||